- Home
- ALIT vs IMVT Comparison
ALIT vs IMVT Comparison
Compare ALIT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALIT
- IMVT
- Stock Information
- Founded
- ALIT 2017
- IMVT N/A
- Country
- ALIT United States
- IMVT United States
- Employees
- ALIT N/A
- IMVT N/A
- Industry
- ALIT Business Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALIT Consumer Discretionary
- IMVT Health Care
- Exchange
- ALIT Nasdaq
- IMVT Nasdaq
- Market Cap
- ALIT 3.5B
- IMVT 3.6B
- IPO Year
- ALIT N/A
- IMVT N/A
- Fundamental
- Price
- ALIT $6.82
- IMVT $21.27
- Analyst Decision
- ALIT Strong Buy
- IMVT Strong Buy
- Analyst Count
- ALIT 9
- IMVT 12
- Target Price
- ALIT $10.61
- IMVT $45.90
- AVG Volume (30 Days)
- ALIT 6.6M
- IMVT 1.5M
- Earning Date
- ALIT 02-20-2025
- IMVT 02-06-2025
- Dividend Yield
- ALIT 1.17%
- IMVT N/A
- EPS Growth
- ALIT N/A
- IMVT N/A
- EPS
- ALIT N/A
- IMVT N/A
- Revenue
- ALIT $2,332,000,000.00
- IMVT N/A
- Revenue This Year
- ALIT $4.80
- IMVT N/A
- Revenue Next Year
- ALIT $4.09
- IMVT N/A
- P/E Ratio
- ALIT N/A
- IMVT N/A
- Revenue Growth
- ALIT N/A
- IMVT N/A
- 52 Week Low
- ALIT $6.15
- IMVT $19.07
- 52 Week High
- ALIT $10.38
- IMVT $39.55
- Technical
- Relative Strength Index (RSI)
- ALIT 51.15
- IMVT 47.11
- Support Level
- ALIT $6.52
- IMVT $20.41
- Resistance Level
- ALIT $7.66
- IMVT $21.43
- Average True Range (ATR)
- ALIT 0.24
- IMVT 1.13
- MACD
- ALIT 0.03
- IMVT 0.23
- Stochastic Oscillator
- ALIT 31.43
- IMVT 54.52
About ALIT Alight Inc.
Alight Inc is a provider of integrated, cloud-based human capital solutions that empower clients and employees to manage health, wealth and HR needs. Geographically, the company generates a majority of its revenue from the United States.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).